Parsec Financial Management Has Trimmed By $699,997 Its Abbott Laboratories (ABT) Position; Fiera Capital Has Upped Its Varian Med Sys (VAR) Position

Abbott Laboratories (NYSE:ABT) Logo

Fiera Capital Corp increased Varian Med Sys Inc (VAR) stake by 7.48% reported in 2018Q3 SEC filing. Fiera Capital Corp acquired 188,505 shares as Varian Med Sys Inc (VAR)’s stock rose 9.42%. The Fiera Capital Corp holds 2.71M shares with $303.36 million value, up from 2.52 million last quarter. Varian Med Sys Inc now has $12.04B valuation. The stock decreased 0.33% or $0.44 during the last trading session, reaching $132.03. About 578,342 shares traded. Varian Medical Systems, Inc. (NYSE:VAR) has risen 6.73% since February 1, 2018 and is uptrending. It has outperformed by 6.73% the S&P500. Some Historical VAR News: 04/05/2018 – SIRTEX MEDICAL LTD SRX.AX – ANY ACQUISITION OF SIRTEX BY CDH WOULD ALSO BE CONDITIONAL ON APPROVAL OF AUSTRALIA’S FOREIGN INVESTMENT REVIEW BOARD; 20/04/2018 – Varian Calypso Anchored Beacon Transponder For Lung Receives FDA 510k Clearance; 22/05/2018 – VARIAN MEDICAL SYSTEMS INC VAR.N – CO IS COMMITTED TO TERMS OF VARIAN SCHEME AT PURCHASE PRICE OFFERED BY VARIAN OF A$28 PER SHARE; 22/05/2018 – SIRTEX MEDICAL LTD SRX.AX – SECOND HALF DOSE SALES ARE EXPECTED TO BE RELATIVELY FLAT VERSUS FIRST HALF; 26/04/2018 – Hospital Alemão Oswaldo Cruz in Brazil Selects Varian Halcyon Cancer Treatment System; 04/05/2018 – VARIAN MEDICAL SYSTEMS SAYS NOTES THAT DIRECTORS OF SIRTEX CONTINUE TO BELIEVE THAT VARIAN SCHEME IS IN BEST INTERESTS OF SIRTEX SHAREHOLDERS; 04/04/2018 – VARIAN MEDICAL SYSTEMS – CREDIT AGREEMENT PROVIDES FOR A 5-YR REVOLVING CREDIT FACILITY OF UP TO $1.8 BLN; 09/03/2018 – Varian Selected by the lnstituto Mexicano del Seguro Social (IMSS) to Equip Seven Treatment Centers in Mexico with Advanced Radiotherapy Technology; 25/04/2018 – VARIAN 2Q ADJ EPS $1.15, EST. $1.04; 13/03/2018 – SIRTEX MEDICAL – U.S. FTC GRANTED EARLY TERMINATION OF WAITING PERIOD UNDER CLAYTON ACT & PREMERGER NOTIFICATION RULES WITH RESPECT TO SCHEME

Parsec Financial Management Inc decreased Abbott Laboratories (ABT) stake by 3.63% reported in 2018Q3 SEC filing. Parsec Financial Management Inc sold 9,589 shares as Abbott Laboratories (ABT)’s stock rose 6.57%. The Parsec Financial Management Inc holds 254,289 shares with $18.66M value, down from 263,878 last quarter. Abbott Laboratories now has $128.18B valuation. It closed at $72.98 lastly. It is down 29.68% since February 1, 2018 and is uptrending. It has outperformed by 29.68% the S&P500. Some Historical ABT News: 18/05/2018 – ABBOTT SAYS IT’S TIME IN TEXAS TO TAKE ACTION TO MAKE SURE SUCH TRAGEDIES ARE NOT REPEATED; 03/05/2018 – ABBOTT EXPANDS CARDIAC ARRHYTHMIAS PORTFOLIO W/ FDA CLEARANCE; 29/03/2018 – ABBOTT LABORATORIES – NEW STUDY WILL EVALUATE WHETHER TREATMENT WITH CARDIOMEMS MONITOR IMPROVES SURVIVAL AND OUTCOMES FOR MORE PEOPLE; 23/05/2018 – Abbott Labs: Tendyne Shows Significant Reduction of Mitral Regurgitation Symptoms and Low Mortality Rates; 29/03/2018 – Cardiovascular: Abbott Initiates Trial to Evaluate Improved Survival And Outcomes with the CardioMEMS Monitor; 11/04/2018 – Abbott: Trial Will Assess if Stent Procedures Guided by High-Resolution Imaging Result in Larger Vessel Diameters and Improved Patient Clinical Outcomes; 19/03/2018 – ABBOTT’S MITRACLIP THERAPY GETS NATIONAL REIMBURSEMENT IN JAPAN; 23/05/2018 – ABBOTT REPORTS POSITIVE OUTCOMES OF TENDYNE DEVICE STUDY; 18/04/2018 – ABBOTT 1Q EARNINGS CALL ENDS; 06/03/2018 – Abbott Labs: FDA OKS Mechanical Heart Valve for Pediatric Patients With Heart Defects

Parsec Financial Management Inc increased Cvs Health Corp (NYSE:CVS) stake by 4,799 shares to 276,373 valued at $21.76M in 2018Q3. It also upped Spdr Portfolio S&P 500 Growth (SPYG) stake by 10,157 shares and now owns 37,225 shares. United Parcel Service Inc Cl B (NYSE:UPS) was raised too.

Investors sentiment increased to 0.96 in 2018 Q3. Its up 0.10, from 0.86 in 2018Q2. It is positive, as 52 investors sold ABT shares while 561 reduced holdings. 153 funds opened positions while 434 raised stakes. 1.23 billion shares or 0.24% more from 1.23 billion shares in 2018Q2 were reported. Private Na reported 46,208 shares stake. Aspiriant Ltd Liability Corporation, California-based fund reported 32,082 shares. Employees Retirement Of Texas owns 0.32% invested in Abbott Laboratories (NYSE:ABT) for 323,662 shares. Freestone Holdings Limited Liability Corp holds 0.02% of its portfolio in Abbott Laboratories (NYSE:ABT) for 42,796 shares. Intersect Ltd Co accumulated 5,335 shares or 0.17% of the stock. Schulhoff holds 1.14% or 27,799 shares in its portfolio. Yacktman Asset Lp stated it has 2,800 shares or 0% of all its holdings. 59,819 are owned by Savant Ltd Liability. Ashfield Cap Ptnrs invested in 108,721 shares. 32,829 were reported by Dodge And Cox. Edgewood Mgmt Ltd Liability reported 0.02% stake. 535,263 are owned by Kornitzer Mgmt Ks. Halsey Associate Inc Ct accumulated 26,468 shares. Moreover, South State has 0.53% invested in Abbott Laboratories (NYSE:ABT) for 69,582 shares. Kingfisher Cap Ltd Liability reported 37,464 shares stake.

Since August 29, 2018, it had 0 insider purchases, and 9 insider sales for $24.81 million activity. Watkin Jared sold $4.62M worth of Abbott Laboratories (NYSE:ABT) on Friday, November 2. 64,268 shares were sold by Contreras Jaime, worth $4.30M. WHITE MILES D also sold $10.30M worth of Abbott Laboratories (NYSE:ABT) on Wednesday, November 28. The insider Bracken Sharon J sold 1,732 shares worth $127,044. 5,000 Abbott Laboratories (NYSE:ABT) shares with value of $366,957 were sold by Salvadori Daniel Gesua Sive. $4.00 million worth of Abbott Laboratories (NYSE:ABT) was sold by Blaser Brian J. On Wednesday, August 29 LANE ANDREW H sold $610,513 worth of Abbott Laboratories (NYSE:ABT) or 9,097 shares.

More notable recent Abbott Laboratories (NYSE:ABT) news were published by: which released: “Abbott’s Cash Flow Machine Keeps On Chugging – Abbott Laboratories (NYSE:ABT) – Seeking Alpha” on January 28, 2019, also with their article: “Abbott Laboratories EPS in-line, misses on revenue – Seeking Alpha” published on January 23, 2019, published: “Sell-Side Issues Positive Prognosis For Abbott (NYSE:ABT) Following Mixed Q4 Results, Strong 2019 Outlook – Benzinga” on January 24, 2019. More interesting news about Abbott Laboratories (NYSE:ABT) were released by: and their article: “Abbott Laboratories Q4 2018 Earnings Preview – Seeking Alpha” published on January 22, 2019 as well as‘s news article titled: “How Safe Is Abbott Laboratories’ Dividend? – Seeking Alpha” with publication date: January 17, 2019.

Among 10 analysts covering Abbott Laboratories (NYSE:ABT), 9 have Buy rating, 1 Sell and 0 Hold. Therefore 90% are positive. Abbott Laboratories had 13 analyst reports since September 24, 2018 according to SRatingsIntel. The firm earned “Overweight” rating on Monday, October 8 by JP Morgan. As per Thursday, October 18, the company rating was maintained by Raymond James. On Thursday, October 11 the stock rating was maintained by Morgan Stanley with “Overweight”. Morgan Stanley maintained the shares of ABT in report on Wednesday, January 2 with “Overweight” rating. The firm has “Outperform” rating given on Monday, September 24 by Raymond James. The firm earned “Outperform” rating on Monday, September 24 by Wells Fargo. The stock of Abbott Laboratories (NYSE:ABT) has “Overweight” rating given on Tuesday, December 4 by Morgan Stanley. The stock of Abbott Laboratories (NYSE:ABT) earned “Buy” rating by Goldman Sachs on Friday, November 30. The company was downgraded on Wednesday, January 2 by Citigroup.

Since August 15, 2018, it had 0 buys, and 13 sales for $3.54 million activity. $308,466 worth of stock was sold by MOMSEN MAGNUS on Thursday, January 3. KENNEDY KOLLEEN T sold 6,462 shares worth $807,750. Another trade for 365 shares valued at $40,150 was sold by KUO JOHN W. Another trade for 10,000 shares valued at $1.11 million was made by GUERTIN TIMOTHY E on Wednesday, September 5. 845 shares valued at $101,603 were sold by BISCHOPING GARY E JR on Wednesday, October 31.

Among 4 analysts covering Varian Medical Systems (NYSE:VAR), 3 have Buy rating, 1 Sell and 0 Hold. Therefore 75% are positive. Varian Medical Systems had 5 analyst reports since October 24, 2018 according to SRatingsIntel. The rating was maintained by Citigroup with “Buy” on Wednesday, October 31. Citigroup maintained it with “Buy” rating and $131 target in Wednesday, January 2 report. JP Morgan maintained the stock with “Underweight” rating in Wednesday, October 24 report. Goldman Sachs upgraded the stock to “Buy” rating in Friday, January 4 report.

More notable recent Varian Medical Systems, Inc. (NYSE:VAR) news were published by: which released: “Varian Medical Systems Q4 2019 Earnings Preview – Seeking Alpha” on January 22, 2019, also with their article: “Varian FQ1 earnings up 192% – Seeking Alpha” published on January 23, 2019, published: “Varian Medical Systems misses by $0.01, beats on revenue – Seeking Alpha” on January 23, 2019. More interesting news about Varian Medical Systems, Inc. (NYSE:VAR) were released by: and their article: “Varian up 7% after Goldman upgrade – Seeking Alpha” published on January 04, 2019 as well as‘s news article titled: “Earnings Scheduled For January 23, 2019 – Benzinga” with publication date: January 23, 2019.

Varian Medical Systems, Inc. (NYSE:VAR) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.